Mr. Weinstein is focused primarily on international business development for Vanterra portfolio companies. Mr. Weinstein has more than 30 years of experience in the healthcare and wellness industries, both operational and investing. Mr. Weinstein is Managing Partner of WM Partners, a leading health and wellness focused private equity fund. Previously, Mr. Weinstein was the CEO of CFR Pharmaceuticals S.A. (also known as Laboratorios Recalcine) (“CFR”) for ten years, where he was responsible for transforming that company from a local Chilean pharmaceutical company into a major global pharmaceutical company with a presence in 26 countries and three continents. During his tenure as CEO, Mr. Weinstein executed more than 15 acquisition transactions in ten different countries, including the acquisition of Lafrancol S.A., the largest pharmaceutical company in Colombia, for over $560 million. During this time, CFR also generated double digit sales growth. Under Mr. Weinstein’s leadership, in May 2011 CFR completed an initial public offering of its equity securities, which was one of the largest IPOs in Chile. In September 2014, Mr. Weinstein led the sale of CFR to Abbott Laboratories for approximately $2.9 billion.
Mr. Weinstein has been active in developing and managing several businesses and start-up companies in the pharmaceutical and healthcare industries, including the Genomika Foundation, a stem cell research organization; the Biomedical Research Consortium, a joint venture between a biotech R&D company and a leading university; Vidacel and Banco de Vida, public and private stem cell banks in Chile; and several other joint ventures with local and foreign R&D companies. Mr. Weinstein has served as a board member in several businesses within the pharmaceutical industry and other industries in three continents.
Mr. Weinstein received a Business and Administration degree from the Universidad Catolica de Chile, and is a certified public auditor and accountant. He participated in the Owner/President Management Program at Harvard Business School.